Gastric effects of subchronic treatment with the cholecystokinin-B (CCK-B)/gastrin receptor antagonist CI-988 were investigated in cynomolgus monkeys. In preliminary range-finding studies, CI-988 was given orally to 1 monkey per sex for 14 days at doses of 50, 100, 200, and 500 mg/kg/day. Subchronic studies of CI-988 were subsequently conducted using 5 monkeys per sex at doses of 0, 5, 25, and 75 mg/kg for 4 or 13 wk. High-dose monkeys were dosed initially at 100 mg/kg, but the dose was not well tolerated and was decreased to 75 mg/kg after 8 days of treatment. One male monkey at 75 mg/kg was euthanatized in extremis on day 23. In the range-finding study, minimal to moderate, multifocal to diffuse degeneration of gastric glands, primarily in the fundic region, was observed at 100 mg/kg and above, with frank gastric mucosal atrophy occurring at 200 and 500 mg/kg. Minimal to mild gastric gland degeneration was also observed in the subchronic study after 4 wk at 25 and 75 mg/kg, but histopathologic gastric changes were remarkably absent after 13 wk. Mucosal height in the stomach fundus was decreased 19.8% in 75-mg/kg males at week 4, and although gastric mucosa appeared histologically normal after 13 wk, mucosal height remained 28.6% less than that of controls. In females at 75 mg/kg, fundic mucosal height was decreased 7% and 5% at weeks 4 and 13, respectively, but decreases were not statistically significant. Mean serum gastrin concentrations were increased 10-fold in males only after 4 wk at 75 mg/kg, but were comparable to controls during week 13. CI-988-induced gastric gland degeneration is consistent with antagonism of gastrin's trophic activity toward gastric mucosa. Notwithstanding decrements in gastric mucosal height, disappearance of mild histopathologic findings despite continued treatment with the ligand suggests some degree of adaptation to subchronic CCK-B/gastrin inhibition, although the mechanism of accomodation has yet to be delineated.
Betton GRDormer CSWells T.Pert P., Price CA and Buckley P. (1988). Gastric ECL-cell hyperplasia and carcinoids in rodents following chronic administration of H2-antagonists SK&F 93479 and oxmetidine and omeprazole. Toxicol. Pathol. 16: 288-298.
2.
Blevins GT Jr.van de Westerlo EMA, Yule DI and Williams JA (1994). Characterization of cholecystokininA receptor agonist activity by a family of cholecystokininB receptor antagonists . J. Pharmacol. Exp. Ther. 269: 911-916.
3.
Brenna E. and Waldum HL (1992). Trophic effect of gastrin on the enterochromaffin-like cells of the rat stomach: Establishment of a dose-response relationship. Gut33: 1303-1306.
4.
Brittain RT, Jack D.Reeves JJ, and Stables R. (1985). Pharmacological basis for the induction of gastric carcinoid tumors in the rat by loxtidine, an unsurmountable histamine H2-receptor blocking drug. Br. J. Pharmacol. 85: 843-847.
5.
Chen D., Uribe A., Hakanson R., and Sundler F. (1992). Somatostatin cells in the oxyntic mucosa of hypo- or hypergastrinemic rats. Scand. J. Gastroenterol. 27: 479-482.
6.
Crawley JN and Corwin RL (1994). Biological actions of cholecystokinin. Peptides15: 731-755.
7.
Creutzfeldt W. (1988). The achlorhydria-carcinoid sequence: Role of gastrin. Digestion39: 61-79.
8.
Dethloff L., Bestervelt LL, Tierney B., and Breider MA (1995). Species specificity for gastric gland atrophy induced by a gastrin receptor antagonist. Toxicologist16: 1708a.
9.
Dethloff L., Hawkins K., and Patmore S. (in press). Dichotomous gastric effects of a cholecystokinin antagonist in the cynomolgus monkey. Food Chem. Toxicol.
10.
Ding XQ, Chen D., and Hakanson R. (1995). Cholecystokinin-B receptor ligands of the dipeptoid series act as agonists on rat stomach histidine decarboxylase. Gastroenterology109: 1181-1187.
11.
Eissele R., Patberg H., Koop H., Krack W., Lorenz W., McKnight AT, and Arnold R. (1992). Effect of gastrin receptor blockade on endocrine cells in rats during achlorhydria. Gastroenterology103: 1596-1601.
Freidinger RM , Gock MG, DiPardo RM, Evans BE, Rittle KE, Witter WL, Veber DF, Anderson PS, Chang RSL, and Lotti VJ (1990). Development of selective nonpeptide CCK-A and CCK-B/ gastrin receptor antagonists. In: The Neuropeptide Cholecystokinin (CCK): Anatomy and Biochemistry, Receptors, Pharmacology and Physiology, J Hughes, GJ Dockray, and G Woodruff (eds). Ellis Horwood, Chichester , pp. 123-132.
14.
Hakanson R., Axelson J., Ihse I., and Sundler F. (1991). The targets for the trophic action of gastrin and cholecsytokinin. In: The Stomach as an Endocrine Organ , R Hakanson and F Sundler (eds). Elsevier, Amsterdam , pp. 307-320.
15.
Hakanson R. , Blom H., Carlsson E.Larsson H., Ryberg B., and Sundler F. (1986). Hypergastrinaemia produces trophic effects in stomach but not in pancreas and intestines. Regul. Pept. 13: 225-233.
16.
Havu N. (1986). Enterochromaffin-like cell carcinoids of gastric mucosa in rats after life-long inhibition of gastric secretion. Digestion35(suppl. 1): 42-55.
17.
Hayward NJ, Harding M., Lloyd SAC, McKnight ATHughes J. and Woodruff GN (1991). The effect of CCKB/gastrin antagonists on stimulated gastric acid secretion in the anesthetized rat. Br. J. Pharmacol . 104: 973-977.
18.
Herrington MK, Permert J.Kazakoff KRZucker KABilchik AJ, Pour PM, and Adrian TE (1994). Effects of raw soya diet and cholecystokinin receptor blockade on pancreatic growth and tumor initiation in the hamster. Cancer Lett. 82: 7-16.
19.
Hinton J.Dethloff L. and Hawkins K. (in press) Toxicokinetic comparisons of a CCK antagonist given orally and intravenously. Drug Dev. Res.
20.
Hughes J., Boden P., Costall B.Domeney A.Kelly E., Horwell D., Hunter JC, Pinnock RD and Woodruff GN (1990). Development of a class of selective cholecystokinin type B receptor antagonists having potent anxiolytic activity. Proc. Natl. Acad. Sci. USA87: 6728-6732.
21.
Hughes J, Dockray G, and Woodruff G (eds) (1989). The Neuropeptide Cholecystokinin (CCK). Ellis Horwood , Chichester, pp. 11-252.
22.
Innis RB and Snyder SH (1980). Distinct cholecystokinin receptors in brain and pancreas. Proc. Natl. Acad. Sci. USA77: 6917-6921.
23.
Johnson LR and Guthrie PD (1974). Secretin inhibition of gastrin-stimulated deoxyribonucleic acid synthesis. Gastroenterology67: 601-606.
24.
Johnson LR and Guthrie PD (1976). Effect of cholecystokinin and 16,16-dimethyl-prostaglandin E2 on RNA and DNA of gastric and duodenal mucosa. Gastroenterology70: 59-65.
25.
Johnson LR and Guthrie PD (1984). Proglumide inhibition of trophic action of pentagastrin . Am. J. Physiol. 246: G62-G66.
26.
Kawabata S. , Kanayama S., Shinomura Y., Miyazaki Y., Imamura I., Morkwaki K., Wada H., and Tarui S. (1991). Effect of cholecystokinin receptor antagonists MK-329 and L-365,260 on cholecystokinin-induced acid secretion and histidine decarboxylase activity in the rat. Regul. Pept.35: 1-10.
27.
Konturek SJ , Bilski J., and Cieszkowski M. (1992). Role of cholecystokinin in the intestinal fat- and acid-induced inhibition of gastric secretion. Regul. Pept. 42: 97-109.
28.
Konturek SJ , Dembinski A., Warzecha Z., Jaworek J., Konturek PK, Cai RZ, and Schally AV (1991). Antagonism of receptors for bombesin, gastrin and cholecystokinin in pancreatic secretion and growth . Digestion48: 89-97.
29.
Langhans N. , Rindi G., Chiu M., Rehfeld JF, Ardman B., Beinborn M., and Kopin AS (1997). Abnormal gastric histology and decreased acid production in cholecystokinin-B/gastrin receptor-deficient mice. Gastroenterology112: 280-286.
30.
Liddle RA (1994). Cholecystokinin. In: Gut Peptides: Biochemistry and Physiology, JH Walsh and GJ Dockray (eds). Raven Press, New York, pp. 175-216.
31.
Meecham K., Turner W., Marvik R., Sandvik A., Waldum HL, and McKnight AT (1994). The effects of the CCKB receptor antagonist CI-988 on acid secretion in mouse isolated stomach. Br. J. Pharmacol . 113(suppl.): 130P.
32.
Meijers M., Appel MJ, van Garderen-Hoetmer A., Lamers Cbhw, Rovati LC, Jansen Jbmj, and Woutersen RA (1992). Effects of cholecystokinin and bombesin on development of azaserine-induced pancreatic tumors in rats: Modulation by the cholecystokinin receptor antagonist lorglumide. Carcinogenesis13: 1525-1528.
33.
Nadzan AM and Kerwin JF Jr (1991). Cholecystokinin agonists and antagonists . Ann. Rep. Med. Chem. 26: 191-200.
34.
Nakano S., Tachibana I., and Otsuki M. (1994). Effects of cholecystokinin receptor antagonist loxiglumide on rat exocrine pancreas. Pancreas9: 425-433.
35.
Nishida A., Kobayashi-Uchida A., Akuzawa S., Takinami Y., Shishido T., Kamato T., Ito H., Yamano M., Yuki H., Nakura Y., Honda K., and Miyata K. (1995). Gastrin receptor antagonist YM022 prevents hypersecretion after long-term acid suppression. Am. J. Physiol. 269: G699-G705.
36.
Ohlsson B., Axelson J., Sternby B., Rehfeld JF, and Ihse I. (1995). Time course of pancreatic changes following long-term stimulation or inhibition of the CCK-A receptor. Int. J. Pancreatol . 18: 59-66.
37.
Pap A., Boros L., and Hajnal F. (1991). Essential role of cholecystokinin in pancreatic regeneration after 60% distal resection in rats. Pancreas6: 412-418.
38.
Papp M., Varga G., and Folly G. (1991). Effect of lorglumide (CR-1409) on pancreatic secretory and trophic response to caerulein in newborn rats. Acta Physiol. Hung. 78: 61-67.
39.
Rivard N., Rydzewska G., Boucher C., Lods JS, Calvo E., and Morriset J. (1994). Cholecystokinin activation of tyrosine kinase, Ptdinositol 3-kinase, and phospholipase D; a role in pancreas growth induction? Endocr. J. 2: 393-401.
40.
Rivard N., Rydzewska G., Lods JS, and Morriset J. (1995). Novel model of integration of signaling pathways in rat pancreatic acinar cells. Am. J. Physiol. 269: G352-G362.
41.
Ryberg B., Axelson J., Hakanson R., Sundler F., and Mattsson H. (1990). Trophic effects of continuous infusion of [leu15]-gastrin-17 in the rat. Gastroenterology98: 33-38.
42.
Ryberg B., Tielemans Y., Axelson J., Carlsson E., Hakanson R., Mattsson H., Sundler F., and Willems G. (1990). Gastrin stimulates the self-replication rate of enterochromaffin-like cells in the rat stomach. Effects of omeprazole, ranitidine, and gastrin-17 in intact and antrectomized rats. Gastroenterology99: 935-942.
43.
Sandvik AK and Waldum HL (1991). CCK-B (gastrin) receptor regulates gastric histamine release and acid secretion. Am. J. Physiol. 260: G925-G928
44.
Schubert ML (1993). Neural and paracrine regulation of gastrin secretion . In: Gastrin, Walsh JH (ed). Raven Press, New York , pp. 129-137.
45.
Selway SAM (1990). Potential hazards of long-term acid suppression. Scand. J. Gastroenterol. 25(suppl. 178): 85-92.
46.
Simon B., Eissele R., Swarovsky B., and Arnold R. (1995). Effect of gastrin receptor blockade on gastrin and histidine decarboxylase gene expression in rats during achlorhydria. Scand . J. Gastroenterol. 30: 503-510.
47.
Tielemans Y. , Axelson J., Sundler F., Willems G., and Hakanson R. (1990). Serum gastrin concentration affects the self-replication rate of the enterochromaffin-like cells in the rat stomach. Gut31: 274-278.
48.
Tielemans Y. , Hakanson R., Sundler F., and Willems, G. (1989). Proliferation of enterochromaffin-like cells in omeprazole-treated hypergastrinemic rats. Gastroenterology96: 723-729.
49.
Tierney BM, Bestervelt LL, and Dethloff LA (1997). The gastrin receptor ligand CI-988 acts as antagonist against proliferation of rat pancreatic AR42J cells. Toxicologist17: 806a.
50.
Walsh JH (1994). Gastrin. In: Gut Peptides: Biochemistry and Physiology, JH Walsh and GJ Dockray (eds). Raven Press, New York, pp. 75-121.
51.
Wank SA (1995). Cholecystokinin receptors. Am. J. Physiol. 269: G628-G646.
52.
Watanapa P. , Efa EF, Beardshall K., Calam J., Sarraf CE, Alison MR, and Williamson RCN (1991 ). Inhibitory effect of a cholecystokinin antagonist on the proliferative response of the pancreas to pancreatobiliary diversion. Gut32: 1049-1054.
53.
Wettstein JG , Bueno L., and Junien JL (1994). CCK antagonists: Pharmacology and therapeutic interest. Pharmacol. Ther. 62: 267-282.
54.
Woodruff GN and Hughes J. (1991). Cholecystokinin antagonists. Annu. Rev. Pharmacol. Toxicol. 31: 469-501.
55.
Wormsley KG (1989). Therapeutic achlorhydria and risk of gastric cancer. Gastroenterol. Jpn. 24: 585-596.
56.
Yardley JH (1994). Pathology of chronic gastritis and duodenitis . In: Gastrointestinal Pathology. International Academy of Pathology Monograph, H Goldman , HD Appelman, and N Kaufman (eds). Williams & Wilkins , Baltimore, pp. 69-143.
